{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T04:39:13Z","timestamp":1690346353118},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T00:00:00Z","timestamp":1409961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s12072-014-9570-4","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T09:49:34Z","timestamp":1409910574000},"page":"540-549","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Meta-analysis of patients with hepatitis C virus genotype 6: 48\u00a0weeks with pegylated interferon and ribavirin is superior to 24\u00a0weeks"],"prefix":"10.1007","volume":"8","author":[{"given":"Nghia H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley A.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany E.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardha","family":"Devaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jencks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,6]]},"reference":[{"key":"9570_CR1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2011.04714.x","volume":"34","author":"DT Chao","year":"2011","unstructured":"Chao DT, Abe K, Nguyen MH. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther. 2011;34:286\u2013296","journal-title":"Aliment Pharmacol Ther"},{"key":"9570_CR2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.12300","volume":"37","author":"LH Nguyen","year":"2013","unstructured":"Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37:921\u2013936","journal-title":"Aliment Pharmacol Ther"},{"key":"9570_CR3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"M Ghany","year":"2009","unstructured":"Ghany M, Strader D, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335\u20131374","journal-title":"Hepatology"},{"key":"9570_CR4","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1542-3565(05)00711-1","volume":"3","author":"MH Nguyen","year":"2005","unstructured":"Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3:S97\u2013S101","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9570_CR5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1572-0241.2008.01793.x","volume":"103","author":"MH Nguyen","year":"2008","unstructured":"Nguyen MH, Trinh HN, Garcia RT, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48\u00a0weeks versus 24\u00a0weeks of peginterferon plus ribavirin. Am J Gastroenterol. 2008;103:1131\u20131135","journal-title":"Am J Gastroenterol"},{"key":"9570_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1086\/591252","volume":"198","author":"J Fung","year":"2008","unstructured":"Fung J, Lai C, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis. 2008;198:808\u2013812","journal-title":"J Infect Dis"},{"key":"9570_CR7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/hep.23889","volume":"52","author":"KDTH Lam","year":"2010","unstructured":"Lam KDTH, Do ST, Nguyen TT, Garcia RT, Nguyen T, Phan QQ, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology. 2010;52:1573\u20131580","journal-title":"Hepatology"},{"key":"9570_CR8","doi-asserted-by":"crossref","unstructured":"Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K. A randomized trial of 48 versus 24\u00a0weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol. 2012;56:1012\u20131018","DOI":"10.1016\/j.jhep.2011.12.020"},{"key":"9570_CR9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000087270","volume":"49","author":"MF Yuen","year":"2006","unstructured":"Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology. 2006;49:96\u201398","journal-title":"Intervirology"},{"key":"9570_CR10","first-page":"A791","volume":"136","author":"N Nguyen","year":"2009","unstructured":"Nguyen N, Vutien P, Trinh H, Garcia R, Wan K, Nguyen H, et al. Treatment response and tolerability to pegylated interferon (PEG Inf) and ribavirin (RBV) in treatment-naive Asian American patients with chronic hepatitis C and genotype 1,2\/3 and 6. Gastroenterology. 2009;136:A791","journal-title":"Gastroenterology"},{"key":"9570_CR11","doi-asserted-by":"crossref","first-page":"810A","DOI":"10.1016\/j.jhep.2010.11.003","volume":"54","author":"TT Pham","year":"2011","unstructured":"Pham TT, Ho DT. An optimal duration of treatment for chronic hepatitis C genotype 6 patients. Hepatology. 2011;54:810A\u2013811A","journal-title":"Hepatology"},{"key":"9570_CR12","first-page":"A840","volume":"136","author":"TT Pham","year":"2009","unstructured":"Pham TT, Ho DT. Pegylated interferon alfa-2a plus ribavirin in chronic Hepatitis C patients with genotype 6. Gastroenterology. 2009;136:A840","journal-title":"Gastroenterology"},{"key":"9570_CR13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195\u20131206","journal-title":"N Engl J Med"},{"key":"9570_CR14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/apt.12551","volume":"39","author":"JM Wantuck","year":"2014","unstructured":"Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Alim Pharmacol Ther. 2014;39:137\u2013147","journal-title":"Alim Pharmacol Ther"},{"key":"9570_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","volume":"13","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13:401\u2013408","journal-title":"Lancet Infect Dis"},{"key":"9570_CR16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-405880-4.00005-6","volume":"67","author":"JM Pawlotsky","year":"2013","unstructured":"Pawlotsky JM. Hepatitis C virus: standard-of-care treatment. Adv Pharmacol. 2013;67:169\u2013215","journal-title":"Adv Pharmacol"},{"key":"9570_CR17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","volume":"39","author":"RS Koff","year":"2014","unstructured":"Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Alim Pharmacol Ther. 2014;39:478\u2013487","journal-title":"Alim Pharmacol Ther"},{"key":"9570_CR18","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1155\/2013\/624986","volume":"27","author":"K Al Naamani","year":"2013","unstructured":"Al Naamani K, Al Sinani S, Deschenes M. Epidemiology and treatment of hepatitis C genotypes 5 and 6. Can J Gastroenterol. 2013;27:e8\u2013e12","journal-title":"Can J Gastroenterol"},{"key":"9570_CR19","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In Higgins JPT Green S, editors Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011"},{"key":"9570_CR20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-0031-1282072","volume":"50","author":"S Mauss","year":"2012","unstructured":"Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, Rockstroh J, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol. 2012;50:441\u2013444","journal-title":"Z Gastroenterol"},{"key":"9570_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2893.2011.01566.x","volume":"19","author":"P Tangkijvanich","year":"2012","unstructured":"Tangkijvanich P, Komolmit P, Mahachai V, Poovorawan K, Akkarathamrongsin S, Poovorawan Y. Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. J Viral Hepat. 2012;19:423\u2013430","journal-title":"J Viral Hepat"},{"key":"9570_CR22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1440-1746.2009.06163.x","volume":"25","author":"O Tsang","year":"2010","unstructured":"Tsang O, Zee J, Chan J, Li R, Kan Y, Li F, et al. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol. 2010;25:766\u2013771","journal-title":"J Gastroenterol Hepatol"},{"key":"9570_CR23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","volume":"17","author":"NH Nguyen","year":"2010","unstructured":"Nguyen NH, VuTien P, Garcia RT, Trinh H, Nguyen H, Nguyen K, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2\/3 vs 6. J Viral Hepat. 2010;17:691\u2013697","journal-title":"J Viral Hepat"},{"key":"9570_CR24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/jvh.12047","volume":"20","author":"W Seto","year":"2013","unstructured":"Seto W, Tsang O, Liu K, Chan J, Wong D, Fung J, et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat. 2013;20:470\u2013477","journal-title":"J Viral Hepat"},{"key":"9570_CR25","doi-asserted-by":"crossref","unstructured":"Shao X, Zhao Z, Cai Q, Zhang X, Gao Z. The dynamic analysis of the Th1\/Th2 ratio during the interferon alpha\/ribavirin combination therapy for HCV genotype 6 infected patients. J Hepatol 2012; 56","DOI":"10.1016\/S0168-8278(12)60166-4"},{"key":"9570_CR26","doi-asserted-by":"crossref","first-page":"829A","DOI":"10.1002\/hep.24551","volume":"54","author":"C Qing-Xian","year":"2011","unstructured":"Qing-Xian C. The high IL-28B CC genotype contribute to the good response of chronic hepatitis C genotype 6 in China. Hepatology. 2011;54:829A\u2013830A","journal-title":"Hepatology"},{"key":"9570_CR27","first-page":"1899A","volume":"58","author":"H Rao","year":"2013","unstructured":"Rao H, Wei L, Yang R, Chen XY, Jia S, Gao Z, et al. IL28B genotype and IFNL4 ss469415590 DG variant are both associated with response to pegylated IFN-alpha and ribavirin therapy in Chinese patients with chronic hepatitis C. Hepatology. 2013;58:1899A","journal-title":"Hepatology"},{"key":"9570_CR28","first-page":"S783","volume":"138","author":"K Lam","year":"2010","unstructured":"Lam K, Trinh H, Do S, Nguyen T, Garcia R, Nguyen T, et al. Randomized controlled trial of pegylated interferon-alpha 2a and ribavirin in patients with treatment-naive chronic hepatitis C genotype 6. Gastroenterology. 2010;138:S783","journal-title":"Gastroenterology"},{"key":"9570_CR29","first-page":"49","volume":"3","author":"TT Pham","year":"2009","unstructured":"Pham TT, Ho DT. Pegylated interferon alfa-2a plus ribavirin in chronic hepatitis C patient with genotype 6. Hepatol Int. 2009;3:49","journal-title":"Hepatol Int"},{"key":"9570_CR30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3350\/cmh.2013.19.1.45","volume":"19","author":"MH Seong","year":"2013","unstructured":"Seong MH, Kil H, Kim JY, Lee SS, Jang ES, Kim JW, et al. Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6. Clin Mol Hepatol. 2013;19:45\u201350","journal-title":"Clin Mol Hepatol"},{"key":"9570_CR31","first-page":"247","volume":"27","author":"P Thanak","year":"2012","unstructured":"Thanak P, Kitiyakara T, Intaraprasong P, Sobhonslidsuk A, Achalanan N, Kamalaporn P, et al. Real-world outcomes of hepatitis C treatment in thai patients. J Gastroenterol Hepatol. 2012;27:247","journal-title":"J Gastroenterol Hepatol"},{"key":"9570_CR32","first-page":"E79","volume":"49","author":"T Weinstein","year":"2009","unstructured":"Weinstein T, Levine J. Early virologic response in children with hepatitis C genotype 6E. J Pediatr Gastroenterol Nutr. 2009;49:E79","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"9570_CR33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","volume":"58","author":"O Lenz","year":"2013","unstructured":"Lenz O, Vijgen L, Berke J, Cummings M, Fevery B, Peeters M, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013;58:445\u2013451","journal-title":"J Hepatol"},{"key":"9570_CR34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/368217","volume":"187","author":"CK Hui","year":"2003","unstructured":"Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai C. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis. 2003;187:1071\u20131074","journal-title":"J Infect Dis"},{"key":"9570_CR35","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.14309\/00000434-201110002-00259","volume":"106","author":"C Bunchorntavakul","year":"2011","unstructured":"Bunchorntavakul C, Siripun A, Chavalitdhamrong D. Fluvastatin monotherapy for the treatment of patients with chronic hepatitis C: a randomized double-blinded placebo-controlled study. Am J Gastroenterol. 2011;106:S102\u2013S103","journal-title":"Am J Gastroenterol"},{"key":"9570_CR36","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1016\/S0168-8278(11)61325-1","volume":"54","author":"T Chu","year":"2011","unstructured":"Chu T, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus P, et al. The effect of host IL28B genotype on early viral kinetics during interferon-free treatment in patients with chronic hepatitis C (CHC). J Hepatol. 2011;54:S521\u2013S522","journal-title":"J Hepatol"},{"key":"9570_CR37","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/j.1572-0241.2006.00831.x","volume":"101","author":"JT Cheng","year":"2006","unstructured":"Cheng JT, Hsien C, Sun HE, Tong M. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol. 2006;101:2737\u20132743","journal-title":"Am J Gastroenterol"},{"key":"9570_CR38","unstructured":"Thi TTP, Ho TD. Impact of single nucleotide polymorphisms of IL28B on SVR in treatment chronic hepatitis C genotype 6 in Vietnamese. Hepatol Int. 2013;7:S366"},{"key":"9570_CR39","unstructured":"Chen X. A prospective, randomized, open-label, multicenter study of response-guided therapy (RGT) for HCV treatment-na\u00efve Chinese patients with chronic hepatitis C. Hepatol Int. 2013;7:S724"},{"key":"9570_CR40","unstructured":"Han B. In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir (GS-7977), no cross resistance to other classes of direct-acting antivirals, and hypersensitivity to ribavirin. Hepatology 2012;56:711A"},{"key":"9570_CR41","unstructured":"Lim JH. Changes in serum lipid profile before and after interferon therapy in patients with chronic hepatitis C. Hepatol Int. 2012;6:170"},{"key":"9570_CR42","unstructured":"Loh PY. Outcome of hepatitis C treatment and effect of treatment dose adjustment in treatment na\u00efve Asian populations. Hepatol Int. 2013;7:S411"},{"key":"9570_CR43","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ajg.2011.40","volume":"106","author":"WK Seto","year":"2011","unstructured":"Seto WK, Tanaka Y, Liu K, Lai CL, Yuen M. The effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. Am J Gastroenterol. 2011;106:1007\u20131008","journal-title":"Am J Gastroenterol"},{"key":"9570_CR44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ncpgasthep1335","volume":"6","author":"N Antaki","year":"2009","unstructured":"Antaki N, Marcellin P. What is the safe duration of therapy for patients infected with HCV genotype 6? Nat Clin Pract Gastroenterol Hepatol. 2009;6:78\u201379","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"9570_CR45","first-page":"682","volume":"26","author":"W Chow","year":"1997","unstructured":"Chow W, Ng H. Hepatitis C, E and G virus\u2014three new viruses identified by molecular biology technique in the last decade. Ann Acad Med Singapore. 1997;26:682\u2013686","journal-title":"Ann Acad Med Singapore"},{"key":"9570_CR46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1440-1746.2012.07067.x","volume":"27","author":"W Lai","year":"2012","unstructured":"Lai W. Viral hepatitis C\u2014Asia-Pacific perspectives and guidelines. J Gastroenterol Hepatol. 2012;27:29","journal-title":"J Gastroenterol Hepatol"},{"key":"9570_CR47","first-page":"47","volume":"5","author":"A Chutaputti","year":"2011","unstructured":"Chutaputti A, et al. Managing HCV genotype 6 patients. Hepatol Int. 2011;5:47\u201348","journal-title":"Hepatol Int"},{"issue":"Suppl 1","key":"9570_CR48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1478-3231.2010.02389.x","volume":"31","author":"JG McHutchison","year":"2011","unstructured":"McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int. 2011;31(Suppl 1):29\u201335","journal-title":"Liver Int"},{"key":"9570_CR49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O\u2019Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798\u2013801","journal-title":"Nature"},{"key":"9570_CR50","first-page":"1855","volume":"58","author":"C Qing-Xian","year":"2013","unstructured":"Qing-Xian C, Zhixin Z, Lin C, et al. Shortened treatment duration in treatment-naive genotype 6 chronic hepatitis C patients with rapid virological response: a randomized controlled trial. Hepatology. 2013;58:1855","journal-title":"Hepatology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-014-9570-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-014-9570-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-014-9570-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T02:55:15Z","timestamp":1598237715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-014-9570-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,6]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["9570"],"URL":"https:\/\/doi.org\/10.1007\/s12072-014-9570-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,6]]}}}